Literature DB >> 10820018

Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets.

L Covic1, A L Gresser, A Kuliopulos.   

Abstract

Thrombin activates platelets in an ordered sequence of events that includes shape change, increase in cytoplasmic Ca(2+), activation of the alphaIIbbeta3 integrin, granule secretion, aggregation, and formation of a stable hemostatic plug. Activation of this process has also been implicated in the pathogenesis of atherosclerosis, stroke, and thrombosis. There are two identified thrombin-activated receptors on the surface of human platelets. PAR1 is a high-affinity thrombin receptor, and PAR4 is a low apparent affinity thrombin receptor of uncertain function. The goal of these studies is to determine the kinetics of thrombin activation of PAR1 and PAR4 and to relate the individual inputs from each receptor to platelet Ca(2+) signaling, secondary autocrine stimulation, and aggregation. Using a combination of PAR-specific peptide ligands and anti-PAR1 reagents, we separated the biphasic thrombin Ca(2+) response of platelets into two discrete components-a rapid spike response caused by PAR1, followed by a slower prolonged response from PAR4. Despite having a 20-70-fold slower rate of activation, PAR4 produces the majority of the integrated Ca(2+) signal that is sustained by the continuous presence of catalytically active thrombin. Surprisingly, PAR4 activation is much more effective than PAR1 activation in mounting secondary autocrine Ca(2+) signals from secreted ADP. The strong ADP response due to activated PAR4, however, requires prior activation of PAR1 as would normally occur during treatment of platelets with thrombin. Thus, the late signal generated by activated PAR4 is not redundant with the early signal from PAR1 and instead serves to greatly extend the high intracellular Ca(2+) levels that support the late phase of the platelet aggregation process.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10820018     DOI: 10.1021/bi9927078

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  72 in total

1.  Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides.

Authors:  Lidija Covic; Amy L Gresser; Joyce Talavera; Steven Swift; Athan Kuliopulos
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

Review 2.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

3.  Mapping human protease-activated receptor 4 (PAR4) homodimer interface to transmembrane helix 4.

Authors:  María de la Fuente; Daniel N Noble; Sheetal Verma; Marvin T Nieman
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

4.  Irreversible platelet activation requires protease-activated receptor 1-mediated signaling to phosphatidylinositol phosphates.

Authors:  Michael Holinstat; Anita M Preininger; Stephen B Milne; W James Hudson; H Alex Brown; Heidi E Hamm
Journal:  Mol Pharmacol       Date:  2009-05-29       Impact factor: 4.436

5.  Allosteric Activation of a G Protein-coupled Receptor with Cell-penetrating Receptor Mimetics.

Authors:  Ping Zhang; Andrew J Leger; James D Baleja; Rajashree Rana; Tiffany Corlin; Nga Nguyen; Georgios Koukos; Andrew Bohm; Lidija Covic; Athan Kuliopulos
Journal:  J Biol Chem       Date:  2015-05-01       Impact factor: 5.157

6.  The chemistry and pharmacology of privileged pyrroloquinazolines.

Authors:  Bo Chao; Bingbing X Li; Xiangshu Xiao
Journal:  Medchemcomm       Date:  2015-04-01       Impact factor: 3.597

7.  A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant.

Authors:  Shauna L French; Claudia Thalmann; Paul F Bray; Lynn E Macdonald; Andrew J Murphy; Mark W Sleeman; Justin R Hamilton
Journal:  Blood Adv       Date:  2018-06-12

8.  Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by α-thrombin.

Authors:  Amal Arachiche; Michele M Mumaw; María de la Fuente; Marvin T Nieman
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

9.  Protease activated receptors in cardiovascular function and disease.

Authors:  Junor A Barnes; Shamjeet Singh; Aldrin V Gomes
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

10.  Protease-activated receptors in cancer: A systematic review.

Authors:  Na Han; Ketao Jin; Kuifeng He; Jiang Cao; Lisong Teng
Journal:  Oncol Lett       Date:  2011-04-08       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.